News Overview

InterAx and nomoko among TOP 100 Swiss Start-ups

InterAx Biotech AG team: a newcomer to the TOP 100 SWISS START-UPS
InterAx Biotech AG team: a newcomer to the TOP 100 SWISS START-UPS

Did you like this article? Please share it.



This summer you voted for PARK INNOVAARE’s residents to help them win the TOP 100 START-UP AWARD. Now we are pleased to congratulate InterAx Biotech AG and nomoko AG on being selected as two of the most innovative and promising Swiss start-ups of 2017 from more than 100,000 other young companies.

The TOP 100 is a label of recognition for the selected start-ups. It is a great pleasure for us to know that based on the expertise of 100 investors and experts, two companies from the PARK INNOVAARE environment were picked as those having the greatest potential to succeed on the market and whose innovations are already on the way to the customer.

InterAx Biotech AG (#65), a spin-off from the ETH Zurich and the Paul Scherrer Institute (PSI), is building a unique drug discovery platform to dramatically reduce costs for the development of novel GPCR drugs with reduced side effects, thereby benefiting patients with unmet medical needs.

And nomoko AG (#25) is developing a compact, ultra-high resolution camera (2 gigapixels) and a tailored 3D modeling pipeline capable of processing petabytes of data; eventually, the models will be enhanced with intelligence. The company was already among the TOP 100 Swiss start-ups last year.

We wish InterAx Biotech AG and nomoko AG every success and look forward to seeing them in even higher positions of the TOP 100 list next year.